SCHEMBL2650163

SCHEMBL2650163

N#Cc1ccccc1-c1cc(Cl)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 2/20 0.43
GABRB3 P28472 2/20 0.43
GABRA3 P34903 2/20 0.43
GABRA1 P14867 1/20 0.43
GABRA5 P31644 1/20 0.41
LRRK2 Q5S007 2/20 0.41
GRIA1 P42261 1/20 0.40
GRIA3 P42263 1/20 0.40
PDE4D Q08499 1/20 0.40
CCR1 P32246 1/20 0.40
CCR5 P51681 1/20 0.40
CCR8 P51685 1/20 0.40
CYP11B2 P19099 1/20 0.39
NUDT1 P36639 1/20 0.39
ESR2 Q92731 1/20 0.39
ALDH1A1 P00352 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31707384 0.81 GABRG2 (0.46) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL2653585 0.81 GABRA1 (0.47) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL28016639 0.80 PTGES (0.44) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL28371953 0.80 CCR1 (0.52) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL973015 0.77 GRIA1 (0.51) GABRG2GABRB3GABRA3GABRA5GRIA1
SCHEMBL30102603 0.77 GRIA1 (0.51) GABRG2GABRB3GABRA3GABRA5GRIA1
SCHEMBL5673245 0.77 CCR1 (0.46) CCR1CCR5CCR8ALDH1A1CYP1A2
SCHEMBL31070227 0.77 GRIA1 (0.51) GABRG2GABRB3GABRA3GABRA5GRIA1
SCHEMBL25253462 0.75 SCN9A (0.48) GRIA1GRIA3PDE4DCCR1CCR5
SCHEMBL28853223 0.75 L3MBTL1 (0.48) LRRK2ALDH1A1CYP1A2CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104650850-A Blue phosphorescent iridium complex and preparation method thereof, and organic electroluminescence device OCEANS KING LIGHTING SCIENCE 2015-05-27 CN disclosed
EP-1383768-B1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2006-09-06 EP disclosed
US-7030128-B2 Central nervous system disorders; anxiolytic agents; anticonvulsants; cognition activators; side effect reduction MERCK SHARP & DOHME LTD. (GB) 2006-04-18 US disclosed
US-20040092533-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2004-05-13 US disclosed
EP-1383768-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2004-01-28 EP disclosed
WO-2002076983-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092533-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors GABRA3, GABRA1, GABRA4 GABRG2 17/4885GABRB3 8/4885GABRA3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.